These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15357981)

  • 1. Isoindolinone ureas: a novel class of KDR kinase inhibitors.
    Curtin ML; Frey RR; Heyman HR; Sarris KA; Steinman DH; Holmes JH; Bousquet PF; Cunha GA; Moskey MD; Ahmed AA; Pease LJ; Glaser KB; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4505-9. PubMed ID: 15357981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thienopyridine urea inhibitors of KDR kinase.
    Heyman HR; Frey RR; Bousquet PF; Cunha GA; Moskey MD; Ahmed AA; Soni NB; Marcotte PA; Pease LJ; Glaser KB; Yates M; Bouska JJ; Albert DH; Black-Schaefer CL; Dandliker PJ; Stewart KD; Rafferty P; Davidsen SK; Michaelides MR; Curtin ML
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1246-9. PubMed ID: 17188869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
    Dai Y; Guo Y; Frey RR; Ji Z; Curtin ML; Ahmed AA; Albert DH; Arnold L; Arries SS; Barlozzari T; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Pease LJ; Stewart KD; Stoll VS; Tapang P; Wishart N; Davidsen SK; Michaelides MR
    J Med Chem; 2005 Sep; 48(19):6066-83. PubMed ID: 16162008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KDR inhibitor with the intramolecular non-bonded interaction: conformation-activity relationships of novel indole-3-carboxamide derivatives.
    Honda T; Nagahara H; Mogi H; Ban M; Aono H
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1782-5. PubMed ID: 21324683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.
    Sammond DM; Nailor KE; Veal JM; Nolte RT; Wang L; Knick VB; Rudolph SK; Truesdale AT; Nartey EN; Stafford JA; Kumar R; Cheung M
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3519-23. PubMed ID: 15990302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.
    Tripathy R; Ghose A; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Aimone LD; Herman JL; Mallamo JP
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1793-8. PubMed ID: 17239587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase.
    Zhao G; Peery RB; Yingling JM
    Anal Biochem; 2007 Jan; 360(2):196-206. PubMed ID: 17141171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.
    Bilodeau MT; Rodman LD; McGaughey GB; Coll KE; Koester TJ; Hoffman WF; Hungate RW; Kendall RL; McFall RC; Rickert KW; Rutledge RZ; Thomas KA
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2941-5. PubMed ID: 15125964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
    Hasegawa M; Nishigaki N; Washio Y; Kano K; Harris PA; Sato H; Mori I; West RI; Shibahara M; Toyoda H; Wang L; Nolte RT; Veal JM; Cheung M
    J Med Chem; 2007 Sep; 50(18):4453-70. PubMed ID: 17676829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative structure-activity relationship and classification analysis of diaryl ureas against vascular endothelial growth factor receptor-2 kinase using linear and non-linear models.
    Sun M; Chen J; Wei H; Yin S; Yang Y; Ji M
    Chem Biol Drug Des; 2009 Jun; 73(6):644-54. PubMed ID: 19635056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
    Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
    J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
    Bauer D; Whittington DA; Coxon A; Bready J; Harriman SP; Patel VF; Polverino A; Harmange JC
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4844-8. PubMed ID: 18682324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors.
    Becknell NC; Zulli AL; Angeles TS; Yang S; Albom MS; Aimone LD; Robinson C; Chang H; Hudkins RL
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5368-72. PubMed ID: 16890434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR.
    Wu Z; Fraley ME; Bilodeau MT; Kaufman ML; Tasber ES; Balitza AE; Hartman GD; Coll KE; Rickert K; Shipman J; Shi B; Sepp-Lorenzino L; Thomas KA
    Bioorg Med Chem Lett; 2004 Feb; 14(4):909-12. PubMed ID: 15012992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.
    Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Moskey MD; Pease LJ; Stewart KD; Yates M; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4326-30. PubMed ID: 16735117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor.
    Kinose F; Roscilli G; Lamartina S; Anderson KD; Bonelli F; Spence SG; Ciliberto G; Vogt TF; Holder DJ; Toniatti C; Thut CJ
    Mol Vis; 2005 May; 11():366-73. PubMed ID: 15951738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors.
    Baindur N; Chadha N; Brandt BM; Asgari D; Patch RJ; Schalk-Hihi C; Carver TE; Petrounia IP; Baumann CA; Ott H; Manthey C; Springer BA; Player MR
    J Med Chem; 2005 Mar; 48(6):1717-20. PubMed ID: 15771417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of 5-substituted-1H-indol-2-yl-1H-quinolin-2-ones: a novel class of KDR kinase inhibitors.
    Kuethe JT; Wong A; Qu C; Smitrovich J; Davies IW; Hughes DL
    J Org Chem; 2005 Apr; 70(7):2555-67. PubMed ID: 15787543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring novel KDR inhibitors based on pharmaco-informatics methodology.
    Kar RK; Suryadevara P; Sahoo BR; Sahoo GC; Dikhit MR; Das P
    SAR QSAR Environ Res; 2013; 24(3):215-34. PubMed ID: 23437769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of edema and infarct volume following focal cerebral ischemia by early but not delayed administration of a novel small molecule KDR kinase inhibitor.
    Foster KA; Regan HK; Danziger AP; Detwiler T; Kwon N; Rickert K; Lynch JJ; Regan CP
    Neurosci Res; 2009 Jan; 63(1):10-6. PubMed ID: 18951929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.